State of the art in CAR T cell therapy for CD19+ B cell malignancies
Matthew J. Frigault and Marcela V. Maus
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Address correspondence to: Marcela V. Maus, Massachusetts General Hospital, 149 13th Street, Room 3.216, Charlestown, Massachusetts 02129, USA. Email: mvmaus@mgh.harvard.edu.
Find articles by Frigault, M. in: JCI | PubMed | Google Scholar
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Address correspondence to: Marcela V. Maus, Massachusetts General Hospital, 149 13th Street, Room 3.216, Charlestown, Massachusetts 02129, USA. Email: mvmaus@mgh.harvard.edu.
Find articles by
Maus, M.
in:
JCI
|
PubMed
|
Google Scholar
|
First published April 1, 2020 - More info
J Clin Invest. 2020;130(4):1586–1594. https://doi.org/10.1172/JCI129208.
© 2020 American Society for Clinical Investigation
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19+ B cell malignancies, multiple clinical trials of CAR T cell therapy directed to CD19 have led to the approval of this therapy by the FDA and the European Medicines Agency for specific indications. Despite strikingly similar efficacy, investigators at multiple centers participating in these studies have observed the nuances of each CAR T cell product, including variability in manufacturing, availability, and toxicity profiles. Here we review state-of-the-art clinical data on CD19-directed CAR T cell therapies in B cell hematologic malignancies, advances made in understanding and modeling associated toxicities, and several exciting advances and creative solutions for overcoming challenges with this therapeutic modality.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2020 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)